Fully human monoclonal antibody for resisting novel coronavirus and application of fully human monoclonal antibody

A monoclonal antibody and coronavirus technology, applied in antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of limited plasma sources of recovered patients, difficulty in large-scale preparation, and risk of disease infection due to batch-to-batch differences
CN112794898AActive Publication Date: 2021-05-14SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
4 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
Publication Date
2021-05-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, and discloses a fully human monoclonal antibody for resisting novel coronavirus and application of the fully human monoclonal antibody. An SARS-CoV2 receptor binding domain (RBD) is used as a probe, flow cytometry is used for screening B lymphocytes of a new coronary pneumonia rehabilitation patient, and the affinity constant of the prepared monoclonal antibody and the RBD is 4.03 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound to find that binding epitopes of the antibody and a host cell receptor (ACE2) are overlapped, binding of the RBD and the ACE2 can be competitively blocked, the virus is prevented from infecting host cells, some genetic mutations of the new coronavirus can be coped with. The median effective concentration (IC50) for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.12 ng / mL, and the application prospect of diagnosing, treating and preventing the new coronal pneumonia is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biomedicine, in particular to a fully human monoclonal antibody against novel coronavirus and its application. Background technique

[0002] The causative agent of novel coronavirus pneumonia (COVID-19) is a novel coronavirus (SARS-CoV2), which can cause severe acute respiratory disease. According to the report of the World Health Organization, the epidemic has spread to 216 countries and regions, causing a large number of casualties. Clinical features of COVID-19 include fever, dry cough and fatigue, respiratory failure, and even death. So far, most of the vaccines used for prevention and specific drugs for the treatment of novel coronavirus pneumonia are still in the stage of clinical trials or emergency use under specific conditions, and their safety and effectiveness need to be further verified.

[0003] SARS-CoV2 belongs to the genus Coronavirus of the Coronaviridae family, and is a class of envelo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More